Details for New Drug Application (NDA): 216018
✉ Email this page to a colleague
The generic ingredient in ASPRUZYO SPRINKLE is ranolazine. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ranolazine profile page.
Summary for 216018
Tradename: | ASPRUZYO SPRINKLE |
Applicant: | Spil |
Ingredient: | ranolazine |
Patents: | 2 |
Suppliers and Packaging for NDA: 216018
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ASPRUZYO SPRINKLE | ranolazine | GRANULES, EXTENDED RELEASE;ORAL | 216018 | NDA | SUN PHARMACEUTICAL INDUSTRIES, INC. | 47335-624 | 47335-624-11 | 1 GRANULE in 1 PACKET (47335-624-11) |
ASPRUZYO SPRINKLE | ranolazine | GRANULES, EXTENDED RELEASE;ORAL | 216018 | NDA | SUN PHARMACEUTICAL INDUSTRIES, INC. | 47335-624 | 47335-624-30 | 30 GRANULE in 1 CARTON (47335-624-30) |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | GRANULES, EXTENDED RELEASE;ORAL | Strength | 500MG | ||||
Approval Date: | Feb 28, 2022 | TE: | RLD: | Yes | |||||
Patent: | 11,510,878 | Patent Expiration: | Jan 24, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | GRANULES, EXTENDED RELEASE;ORAL | Strength | 1GM | ||||
Approval Date: | Feb 28, 2022 | TE: | RLD: | Yes | |||||
Patent: | 10,898,444 | Patent Expiration: | Jan 24, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | 11,510,878 | Patent Expiration: | Jan 24, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription